WO1999015508A1 - Antagonistes du recepteur de la vitronectine - Google Patents

Antagonistes du recepteur de la vitronectine Download PDF

Info

Publication number
WO1999015508A1
WO1999015508A1 PCT/US1998/019466 US9819466W WO9915508A1 WO 1999015508 A1 WO1999015508 A1 WO 1999015508A1 US 9819466 W US9819466 W US 9819466W WO 9915508 A1 WO9915508 A1 WO 9915508A1
Authority
WO
WIPO (PCT)
Prior art keywords
dihydro
dibenzo
cycloheptene
propyloxy
ylamino
Prior art date
Application number
PCT/US1998/019466
Other languages
English (en)
Inventor
William E. Bondinell
William H. Miller
Dirk Heerding
James Martin Samanen
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020007002901A priority Critical patent/KR20010024141A/ko
Priority to BR9812340-8A priority patent/BR9812340A/pt
Priority to EA200000336A priority patent/EA200000336A1/ru
Priority to NZ503389A priority patent/NZ503389A/en
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to APAP/P/2000/001766A priority patent/AP2000001766A0/en
Priority to CA002303487A priority patent/CA2303487A1/fr
Priority to SK408-2000A priority patent/SK4082000A3/sk
Priority to EP98947116A priority patent/EP1025090A4/fr
Priority to AU93972/98A priority patent/AU738433B2/en
Priority to IL13502898A priority patent/IL135028A0/xx
Priority to JP2000512816A priority patent/JP2001517658A/ja
Priority to HU0003641A priority patent/HUP0003641A3/hu
Publication of WO1999015508A1 publication Critical patent/WO1999015508A1/fr
Priority to NO20001407A priority patent/NO20001407D0/no
Priority to BG104314A priority patent/BG104314A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14—[b,f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • This invention relates to pharmaceutically active compounds which inhibit the vitronectin receptor and are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporosis.
  • Integrins are a superfamily of cell adhesion receptors, which are transmembrane glycoproteins expressed on a variety of cells. These cell surface adhesion receptors include gpllb /Ilia (the fibrinogen receptor) and a v B3 (the vitronectin receptor). The fibrinogen receptor gpllb /Ilia is expressed on the platelet surface, and mediates platelet aggregation and the formation of a hemostatic clot at the site of a bleeding wound. Philips, et al., Blood., 1988, 77, 831.
  • the vitronectin receptor ⁇ v B3 is expressed on a number of cells, including endothelial, smooth muscle, osteoclast, and tumor cells, and, thus, it has a variety of functions.
  • the ⁇ v B 3 receptor expressed on the membrane of osteoclast cells mediates the adhesion of osteoclasts to the bone matrix, a key step in the bone resorption process. Ross, et al., J. Biol. Chem., 1987, 262, 7703.
  • a disease characterized by excessive bone resorption is osteoporosis.
  • the (X V B3 receptor expressed on human aortic smooth muscle cells mediates their migration into neointima, a process which can lead to restenosis after percutaneous coronary angioplasty.
  • o v B3 antagonist is able to promote tumor regression by inducing apoptosis of angiogenic blood vessels.
  • agents that block the vitronectin receptor would be useful in treating diseases, such as osteoporosis, restenosis and cancer.
  • the vitronectin receptor is now known to refer to three different integrins, designated oc v B ⁇ , a v B3 and 0 ⁇ 65. Horton, et al., Int. J. Exp. Pathol., 1990, 77, 741.
  • ⁇ v B ⁇ binds fibronectin and vitronectin.
  • 0 ⁇ 63 binds a large variety of ligands, including fibrin, fibrinogen, laminin, thrombospondin, vitronectin, von Willebrand's factor, osteopontin and bone sialoprotein I.
  • 0 ⁇ 65 binds vitronectin.
  • the vitronectin receptor v B5 has been shown to be involved in cell adhesion of a variety of cell types, including microvascular endothelial cells, (Davis, et al., J. Cell. Biol., 1993, 57, 206), and its role in angiogenesis has been confirmed. Brooks, et al., Science, 1994, 264, 569. This integrin is expressed on blood vessels in human wound granulation tissue, but not in normal skin. The vitronectin receptor is known to bind to bone matrix proteins which contain the tri-peptide Arg-Gly-Asp (or RGD) motif. Thus, Horton, et al., Exp. Cell Res.
  • This invention comprises compounds of the formula (I) as described hereinafter, which have pharmacological activity for the inhibition of the vitronection receptor and are useful in the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporosis.
  • This invention is also a pharmaceutical composition
  • a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically carrier.
  • This invention is also a method of treating diseases which are mediated by the vitronectin receptor.
  • the compounds of this invention are useful for treating atherosclerosis, restenosis, inflammation, cancer and diseases wherein bone resorption is a factor, such as osteoporosis.
  • This invention comprises novel compounds which are more potent inhibitors of the vitronectin receptor than the fibrinogen receptor.
  • the novel compounds comprise a dibenzocycloheptene core in which a nitrogen-containing substituent is present on one of the aromatic six-membered rings of the dibenzocycloheptene and an aliphatic substituent containing an acidic moiety is present on the seven-membered ring of the dibenzocycloheptene.
  • the dibenzocycloheptene ring system is believed to orient the substituent sidechains on the six and seven membered rings so that they may interact favorably with the vitronectin receptor.
  • This invention comprises compounds of formula (I):
  • A is CH 2 or O
  • R 1 is H, halo or C ⁇ .galkyl
  • R 2 is H, C ⁇ _ 6 alkyl or CH 2 NR"R";
  • X is O or CH 2 ;
  • G is NR", S or O;
  • R' is H, Ci- ⁇ alkyl, OCi- ⁇ alkyl, SCi- ⁇ alkyl, NR"R" or halo; each R" independently is H or Ci.galkyl; and s is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.
  • compositions of this invention are also included in this invention.
  • this invention includes each unique nonracemic compound which may be synthesized and resolved by conventional techniques.
  • compounds have unsaturated carbon-carbon double bonds, both the cis (Z) and trans (E) isomers are within the scope of this invention.
  • the compounds of formula (I) inhibit the binding of vitronectin and other RGD- containing peptides to the vitronectin receptor.
  • Inhibition of the vitronectin receptor on osteoclasts inhibits osteoclastic bone resorption and is useful in the treatment of diseases wherein bone resorption is associated with pathology, such as osteoporosis and osteoarthritis.
  • this invention is a method for stimulating bone formation which comprises administering a compound which causes an increase in osteocalcin release.
  • Increased bone production is a clear benefit in disease states wherein there is a deficiency of mineralized bone mass or remodeling of bone is desired, such as fracture healing and the prevention of bone fractures.
  • Diseases and metabolic disorders which result in loss of bone structure would also benefit from such treatment. For instance, hyperparathyroidism, Paget's disease, hypercalcemia of malignancy, osteolytic lesions produced by bone metastasis, bone loss due to immobilization or sex hormone deficiency, Behcet's disease, osteomalacia, hyperostosis and osteopetrosis, could benefit from administering a compound of this invention.
  • the compounds of the instant invention inhibit vitronectin receptors on a number of different types of cells, said compounds would be useful in the treatment of inflammatory disorders, such as rheumatoid arthritis and psoriasis, and cardiovascular diseases, such as atherosclerosis and restenosis.
  • inflammatory disorders such as rheumatoid arthritis and psoriasis
  • cardiovascular diseases such as atherosclerosis and restenosis.
  • the compounds of Formula (I) of the present invention may be useful for the treatment or prevention of other diseases including, but not limited to, thromboembolic disorders, asthma, allergies, adult respiratory distress syndrome, graft versus host disease, organ transplant rejection, septic shock, eczema, contact dermatitis, inflammatory bowel disease, and other autoimmune diseases.
  • the compounds of the present invention may also be useful for wound healing.
  • the compounds of the present invention are also useful for the treatment, including prevention, of angiogenic disorders.
  • angiogenic disorders as used herein includes conditions involving abnormal neovascularization.
  • angiogenisis will reduce the deleterious effects of the disease.
  • An example of such a disease target is diabetic retinopathy.
  • inhibition of angiogenisis will reduce the blood supply to the tissue and thereby contribute to reduction in tissue mass based on blood supply requirements. Examples include growth of tumors where neovascularization is a continual requirement in order that the tumor grow and the establishment of solid tumor metastases.
  • the compounds of the present invention inhibit tumor tissue angiogenesis, thereby preventing tumor metastasis and tumor growth.
  • the inhibition of angiogenesis using the compounds of the present invention can ameliorate the symptoms of the disease, and, in some cases, can cure the disease.
  • eye diseases chacterized by neovascularization include corneal neovascular disorders, such as corneal transplantation, herpetic keratitis, luetic keratitis, pterygium and neovascular pannus associated with contact lens use. Additional eye diseases also include age-related macular degeneration, presumed ocular histoplasmosis, retinopathy of prematurity and neovascular glaucoma.
  • This invention further provides a method of inhibiting tumor growth which comprises administering stepwise or in physical combination a compound of formula (I) and an antineoplastic agent, such as topotecan and cisplatin.
  • R' is H, C ] _ alkyl, OC ⁇ alkyl, SC ⁇ _ 4 alkyl, NR"R” or Cl and each R" independently is H or C ⁇ _ 4 alkyl.
  • Y is
  • each R" is H or C ⁇ _ 4 alkyl.
  • each R" independently is H or C j . 4 alkyl, and s is 1.
  • Y is
  • novel compounds of this invention are the following: (+)- 10,11 -Dihydro-3-[2-(6-aminopyridin-2-yl)- 1 -ethoxy]-5H- dibenzo[a,d]cycloheptene-10-acetic acid;
  • this invention includes each unique nonracemic compound which may be synthesized and resolved by conventional techniques. According to the present invention, the (S) configuration of the formula (I) compounds is preferred.
  • prodrugs of the compounds of this invention are considered to be any covalently bonded carriers which release the active parent drug according to formula (I) in vivo.
  • novel prodrugs which are also intermediates in the preparation of formula (I) compounds, of formula (II):
  • A is CH 2 or O
  • R 1 isH, haloorC ⁇ 6 alkyl
  • R 2 is H, Ci-6alkyl or CH 2 NR"R";
  • X is O or CH ;
  • R' is H, C ⁇ _6alkyl, OCi ⁇ alkyl, SCi- ⁇ alkyl, NR"R" or halo; each R" independently is H or C ⁇ alkyl; and s is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.
  • A is CH 2 or O;
  • R 1 is H, halo or C j .galkyl;
  • R 2 is H, C i _6alkyl or CH 2 NR"R" ;
  • X is O or CH 2 ;
  • R' is H, C ⁇ _6alkyl, OC] -6 alkyl, SC ⁇ _ 6 alkyl, NR"R" or halo; and each R" independently is H or Ci.galkyl; or a pharmaceutically acceptable salt thereof.
  • Abbreviations and symbols commonly used in the peptide and chemical arts are used herein to describe the compounds of this invention. In general, the amino acid abbreviations follow the IUPAC-IUB Joint Commission on Biochemical Nomenclature as described in Eur. J. Biochem., 158, 9 (1984).
  • alkyl as applied herein means an optionally substituted alkyl group of 1 to 4 carbon atoms, and includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl.
  • Ci.galkyl additionally includes pentyl, n-pentyl, isopentyl, neopentyl and hexyl and the simple aliphatic isomers thereof.
  • Co -4 alkyl and C ⁇ _6alkyl additionally indicates that no alkyl group need be present (e.g., that a covalent bond is present).
  • Any C ] . 4 alkyl or C j .g alkyl may be optionally substituted with the group R x , which may be on any carbon atom that results in a stable structure and is available by conventional synthetic techniques.
  • Suitable groups for R x are C ⁇ _ alkyl, OR " , SR " , C 1 .
  • Halogen or halo means F, Cl, Br, and I.
  • Ar, or aryl as applied herein, means phenyl or naphthyl, or phenyl or naphthyl substituted by one to three substituents, such as those defined above for alkyl, especially C 1 . 4 alkyl, C ⁇ 4 alkoxy, C M alkthio, CF 3 , NH 2 , OH, F, Cl, Br or I.
  • t-Bu refers to the tertiary butyl radical
  • Boc refers to the t-butyloxycarbonyl radical
  • Fmoc refers to the fluorenylmethoxycarbonyl radical
  • Ph refers to the phenyl radical
  • Cbz refers to the benzyloxycarbonyl radical
  • Bn refers to the benzyl radical
  • Me refers to methyl
  • Et refers to ethyl
  • Ac refers to acetyl
  • Alk refers to Cj. 4 alkyl
  • Nph refers to 1- or 2-naphthyl
  • cHex refers to cyclohexyl.
  • Tet refers to 5-tetrazolyl.
  • DCC refers to dicyclohexylcarbodiimide
  • DMAP refers to dimethylaminopyridine
  • DIEA refers to diisopropylethyl amine
  • EDC refers to l-(3-dimethylaminopropyl)-3-ethylcarbodiimide, hydrochloride.
  • HOBt refers to 1-hydroxybenzotriazole
  • THF refers to tetrahydrofuran
  • DIEA diisopropylethylamine
  • DEAD refers to diethyl azodicarboxylate
  • PPh3 refers to triphenylphosphine
  • DIAD diisopropyl azodicarboxylate
  • DME dimethoxyethane
  • DMF dimethylformamide
  • NBS refers to N-bromosuccinimide
  • Pd/C refers to a palladium on carbon catalyst
  • PPA refers to polyphosphoric acid
  • DPPA refers to diphenylphosphoryl azide
  • BOP refers to benzotriazol-l-yloxy-tris(dimethyl- amino)phosphonium hexafluorophosphate
  • HF refers to hydrofluoric acid
  • TEA refers to triethylamine
  • TFA trifluoroacetic acid
  • PCC
  • the compounds of formula (I) are generally prepared by reacting a compound of formula (IV) with a compound of formula (V):
  • R ⁇ R 2 , R', R" and A are as defined in formula (I), with any reactive functional groups protected; and thereafter removing any protecting groups, and optionally forming a pharmaceutically acceptable salt.
  • reaction between a compound of formual (IV) with a compound of formula (VI) is carried out in the presence of diethyl azodicarboxylate and triphenylphosphine in an aprotic solvent.
  • R , R 2 , R" and A are as defined in formula (I), with any reactive functional groups protected; and thereafter removing any protecting groups, and optionally forming a pharmaceutically acceptable salt.
  • reaction between a compound of formual (IV) with a compound of formula (VII) is carried out in the presence of diethyl azodicarboxylate and triphenylphosphine in an aprotic solvent.
  • Scheme I details the preparation of an intermediate useful in the preparation of formula (I) compounds.
  • Scheme II also details the preparation of an intermediate useful in the preparation of formula (I) compounds.
  • III-2 Reduction of III-2 to give III-3 (which is a Scheme II-6 compound) can be accomplished by hydrogenolysis over an appropriate catalyst, for example palladium metal on activated carbon (Pd/C), in an appropriate solvent, such as acetic acid, in the presence of a mineral acid such as HC1.
  • an appropriate catalyst for example palladium metal on activated carbon (Pd/C)
  • Pd/C palladium metal on activated carbon
  • acetic acid such as acetic acid
  • this reduction can be accomplished by treatment of III-2 with triethylsilane in the presence of boron trifluoride etherate by the general method of Orfanopoulos and Smonou (Synth. Commun. 1988, 833).
  • III-4 Removal of the methyl ether of III-3 to give III-4 can be accomplished with BBr3 in an inert solvent, for example CH 2 C1 2 , or by reaction with ethanethiol and AICI3 in an inert solvent, preferably CH C1 2 .
  • inert solvent for example CH 2 C1 2
  • ethanethiol and AICI3 in an inert solvent, preferably CH C1 2 .
  • Other useful methods for removal of a methyl ether are described in Greene, "Protective Groups in Organic Synthesis" (published by John Wiley and Sons).
  • Scheme 3 (III-4) is reacted with 2-[(3-hydroxy-l-propyl)amino]-4-nitropyridine-N-oxide in a Mitsunobu-type coupling reaction (Organic Reactions 1992, 42, 335-656; Synthesis 1981, 1-28) to afford III-5.
  • the reaction is mediated by the complex formed between diethyl azodicarboxylate and triphenylphosphine, and is conducted in an aprotic solvent, for instance THF, CH 2 C1 2 , or DMF.
  • Compound III-5 is reacted with an alkali metal salt of an appropriate alcohol to afford III-6.
  • Suitable alkali metals include lithium, sodium, potassium, and cesium, and the alcohol used for the displacement reaction is generally used as the solvent. Methods for forming the alkali metal salts of alcohols are well-known to those of skill in the art.
  • the pyridine-N-oxide moiety of III-6 is reduced to the corresponding pyridine III-7 under transfer hydrogenation conditions using a palladium catalyst, preferably palladium metal on activated carbon, in an inert solvent, for instance methanol, ethanol, or 2-propanol.
  • a palladium catalyst preferably palladium metal on activated carbon
  • an inert solvent for instance methanol, ethanol, or 2-propanol.
  • Cyclohexene, 1 ,4-cyclohexadiene, formic acid, and salts of formic acid, such as potassium formate or ammonium formate are commonly used as the hydrogen transfer reagent in this type of reaction.
  • the ethyl ester of III-7 is hydrolyzed using aqueous base, for example, LiOH in aqueous THF or NaOH in aqueous methanol or ethanol, and the intermediate carboxylate salt is acidified with a suitable acid, for instance TFA or HC1, to afford the carboxylic acid III-8.
  • aqueous base for example, LiOH in aqueous THF or NaOH in aqueous methanol or ethanol
  • the intermediate carboxylate salt is acidified with a suitable acid, for instance TFA or HC1, to afford the carboxylic acid III-8.
  • the intermediate carboxylate salt can be isolated, if desired, or a carboxylate salt of the free carboxvlic acid can be prepared by methods well-known to those of skill in the art.
  • Scheme IV describes an alternative method for the preparation of formula (I) compounds.
  • Compound IV-1 is reacted with a base, preferably an alkali metal hydride such as sodium hydride or potassium hydride, in a polar, aprotic solvent, generally THF, DMF, DMSO, or mixtures thereof, to afford the corresponding alkali metal phenoxide.
  • a base preferably an alkali metal hydride such as sodium hydride or potassium hydride
  • a polar, aprotic solvent generally THF, DMF, DMSO, or mixtures thereof.
  • an alkali metal amide for instance LDA, or the lithium, sodium, or potassium salt of hexamethyldisilazane, can be used for deprotonation.
  • the intermediate phenoxide is generally not isolated, but is reacted in situ with an appropriate electrophile, for instance 2-[N-(3-methanesulfonyloxy-l-propyl)-N-(rert-butoxycarbonyl)- amino]pyridine-N-oxide, to afford the coupled product IV-2.
  • an appropriate electrophile for instance 2-[N-(3-methanesulfonyloxy-l-propyl)-N-(rert-butoxycarbonyl)- amino]pyridine-N-oxide, to afford the coupled product IV-2.
  • the tert-butoxycarbonyl protecting group in IV-2 is removed under acidic conditions, such as 4 M HCl in 1 ,4- dioxane or TFA in CH 2 C1 2 , to afford IV-3.
  • V-l 2-fluoro-4-methoxyacetophenone
  • an alcohol for example phenol
  • copper metal for instance copper metal
  • a suitable base for instance K 2 C0 3
  • V-2 is converted to V-3 in a classical Willgerodt-Kindler reaction.
  • the thioamide thus obtained is hydrolyzed to the corresponding carboxylic acid V-4 by reaction with an alkali metal hydroxide, suitably KOH, in an aqueous alcoholic solvent, such as aqueous MeOH, EtOH, or i-PrOH.
  • Carboxylic acid V-4 is converted to the corresponding acid chloride by reaction with either SOCl or oxalyl chloride according to conditions well-known to those of skill in the art.
  • Treatment of this acid chloride with an appropriate Friedel-Crafts catalyst, such as A1C1 3 or SnCl 4 , in an inert solvent, such as CH 2 C1 2 or CS 2 provides the cyclic ketone V-5.
  • acid V-4 can be converted directly to ketone V-5 under acidic conditions, for example with polyphosphoric acid.
  • Reaction of V-5 in an aldol - type reaction with the enolate of ethyl acetate, which can be generated from ethyl acetate on exposure to an appropriate amide base, for instance lithium diisopropylamide (LDA) or lithium bis(trimethylsilyl)amide (LiHMDS) gives V-6.
  • LDA lithium diisopropylamide
  • LiHMDS lithium bis(trimethylsilyl)amide
  • THF is the solvent of choice for an aldol reaction, although THF in the presence of various additives, for instance HMPA or TMEDA, is often used.
  • V-6 to give V-7 can be accomplished by treatment of V-6 with triethylsilane in the presence of boron trifluoride etherate by the general method of Orphanopoulos and Smonu (Synth. Commun. 1988, 833). Any olefinic by-products that result from elimination of the alcohol are reduced by hydrogenation over an appropriate catalyst, for example palladium metal on activated carbon (Pd/C), in an appropriate solvent, such as MeOH or EtOH. Alternatively, the reduction of V-6 to give V-7 can be accomplished by hydrogenolysis in the presence of a mineral acid such as HCl. Typically, this reaction is catalyzed by Pd/C, and is optimally conducted in acetic acid.
  • Pd/C palladium metal on activated carbon
  • V-8 Removal of the methyl ether of V-7 to give V-8 can be accomplished with BBr 3 in an inert solvent, for example CH 2 C1 2 , or by reaction with ethanethiol and A1C1 3 in an inert solvent, preferably CH 2 C1 .
  • inert solvent for example CH 2 C1 2
  • ethanethiol and A1C1 3 inert solvent, preferably CH 2 C1 .
  • Other useful methods for removal of a methyl ether are described in Greene, "Protective Groups in Organic Synthesis” (published by John Wiley and Sons).
  • V-8 is subsequently converted to formula (I) compounds following the procedure outlined in Scheme III.
  • Acid addition salts of the compounds are prepared in a standard manner in a suitable solvent from the parent compound and an excess of an acid, such as hydrochloric, hydrobromic, hydrofluoric, sulfuric, phosphoric, acetic, trifluoroacetic, maleic, succinic or methanesulfonic. Certain of the compounds form inner salts or zwitterions which may be acceptable.
  • Cationic salts are prepared by treating the parent compound with an excess of an alkaline reagent, such as a hydroxide, carbonate or alkoxide, containing the appropriate cation; or with an appropriate organic amine. Cations such as Li + , Na + , K + , Ca ++ , Mg ++ and NH 4 + are specific examples of cations present in pharmaceutically acceptable salts.
  • compositions which comprises a compound according to formula (I) and a pharmaceutically acceptable carrier.
  • the compounds of formula (I) may be used in the manufacture of a medicament.
  • Pharmaceutical compositions of the compounds of formula (I) prepared as hereinbefore described may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use.
  • the liquid formulation may be a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution.
  • Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate. Alternately, these compounds may be encapsulated, tableted or prepared in a emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
  • Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
  • Liquid carriers include syrup, peanut oil, olive oil, saline and water.
  • the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit.
  • the pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms.
  • a liquid carrier When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension.
  • Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.
  • the compounds of this invention may also be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository.
  • the compounds described herein are antagonists of the vitronectin receptor, and are useful for treating diseases wherein the underlying pathology is attributable to ligand or cell which interacts with the vitronectin receptor. For instance, these compounds are useful for the treatment of diseases wherein loss of the bone matrix creates pathology.
  • the instant compounds are useful for the treatment of ostoeporosis, hyperparathyroidism, Paget's disease, hypercalcemia of malignancy, osteolytic lesions produced by bone metastasis, bone loss due to immobilization or sex hormone deficiency.
  • the compounds of this invention are also believed to have utility as antitumor, anti-angiogenic, antiinflammatory and anti-metastatic agents, and be useful in the treatment of atherosclerosis and restenosis.
  • the compound is administered either orally or parenterally to the patient, in a manner such that the concentration of drug is sufficient to inhibit bone resorption, or other such indication.
  • the pharmaceutical composition containing the compound is administered at an oral dose of between about 0.1 to about 50 mg/kg in a manner consistent with the condition of the patient. Preferably the oral dose would be about 0.5 to about 20 mg/kg. For acute therapy, parenteral administration is preferred.
  • an intravenous infusion of the peptide in 5% dextrose in water or normal saline, or a similar formulation with suitable excipients is most effective, although an intramuscular bolus injection is also useful.
  • the parenteral dose will be about 0.01 to about 100 mg/kg; preferably between 0.1 and 20 mg/kg.
  • the compounds are administered one to four times daily at a level to achieve a total daily dose of about 0.4 to about 400 mg/kg/day.
  • the precise level and method by which the compounds are administered is readily determined by one routinely skilled in the art by comparing the blood level of the agent to the concentration required to have a therapeutic effect.
  • This invention further provides a method for treating osteoporosis or inhibiting bone loss which comprises administering stepwise or in physical combination a compound of formula (I) and other inhibitors of bone resorption, such as bisphosphonates (i.e., allendronate), hormone replacement therapy, anti-estrogens, or calcitonin.
  • this invention provides a method of treatment using a compound of this invention and an anabolic agent, such as the bone morphogenic protein, iproflavone, useful in the prevention of bone loss and/or to increase bone mass.
  • this invention provides a method of inhibiting tumor growth which comprises administering stepwise or in physical combination a compound of formula (I) and an antineoplastic agent.
  • a compound of formula (I) and an antineoplastic agent such as topotecan, irinotecan and 9-aminocamptothecin, and platinum coordination complexes, such as cisplatin, ormaplatin and tetraplatin.
  • platinum coordination complexes such as cisplatin, ormaplatin and tetraplatin.
  • Compounds of the camptothecin analog class are described in U.S. Patent Nos. 5,004,758, 4,604,463, 4,473,692, 4,545,8804,342,776, 4,513,138, 4,399,276, EP Patent Application Publication Nos .
  • the platinum coordination compound for example cisplatin
  • the platinum coordination compound can be administered using slow intravenous infusion.
  • the preferred carrier is a dextrose/saline solution containing mannitol.
  • the dose schedule of the platinum coordination compound may be on the basis of from about 1 to about 500 mg per square meter (mg/m 2 ) of body surface area per course of treatment. Infusions of the platinum coordiation compound may be given one to two times weekly, and the weekly treatments may be repeated several times.
  • the course of therapy generally employed is from about 0.1 to about 300.0 mg/m 2 of body surface area per day for about five consecutive days.
  • the course of therapy employed for topotecan is from about 1.0 to about 2.0 mg/m 2 of body surface area per day for about five consecutive days.
  • the course of therapy is repeated at least once at about a seven day to about a twenty-eight day interval.
  • the pharmaceutical composition may be formulated with both the compound of formula (I) and the antineoplastic agent in the same container, but formualtion in different containers is preferred.
  • both agents are provided in solution form, they can be contained in an infusion/injection system for simultaneous administration or in a tandem arrangement.
  • kits for convenient administration of the compound of formula (I) and the antineoplastic agent at the same or different times, comprising, in a single container, such as a box, carton or other container, individual bottles, bags, vials or other containers each having an effective amount of the compound of formula (I) for parenteral administration, as described above, and an effective amount of the antineoplastic agent for parenteral administration, as described above.
  • kit can comprise, for example, both pharmaceutical agents in separate containers or the same container, optionally as lyophilized plugs, and containers of solutions for reconstitution.
  • a variation of this is to include the solution for reconstitution and the lyophilized plug in two chambers of a single container, which can be caused to admix prior to use.
  • the antineoplastic agent and the compound of this invention may be packaged separately, as in two containers, or lyophilized together as a powder and provided in a single container.
  • both agents are provided in solution form, they can be contained in an infusion/injection system for simultaneous administration or in a tandem arrangement.
  • the compound of formula (I) may be in an i.v. injectable form, or infusion bag linked in series, via tubing, to the antineoplastic agent in a second infusion bag.
  • a patient can receive an initial bolus-type injection or infusion of the compound of formula (I) followed by an infusion of the antineoplastic agent.
  • the compounds may be tested in one of several biological assays to determine the concentration of compound which is required to have a given pharmacological effect.
  • Solid-Phase [ ⁇ H]-SK&F-107260 Binding to cc v ⁇ s Human placenta or human platelet ⁇ v ⁇ 3 (0.1-0.3 mg/mL) in buffer T (containing 2 mM CaCl and 1% octylglucoside) was diluted with buffer T containing 1 mM CaCl , 1 mM MnCl , 1 mM MgCl 2 (buffer A) and 0.05% NaN 3 , and then immediately added to 96-well ELISA plates (Corning, New York, NY) at 0.1 mL per well. 0.1 - 0.2 ⁇ g of ⁇ v ⁇ 3 was added per well.
  • the plates were incubated overnight at 4°C. At the time of the experiment, the wells were washed once with buffer A and were incubated with 0.1 mL of 3.5% bovine serum albumin in the same buffer for 1 hr at room temperature. Following incubation the wells were aspirated completely and washed twice with 0.2 mL buffer A.
  • the plates were incubated for 1 hr at room temperature. Following incubation the wells were aspirated completely and washed once with 0.2 mL of ice cold buffer A in a well-to- well fashion.
  • the receptors were solubilized with 0.1 mL of 1% SDS and the bound H]-SK&F- 107260 was determined by liquid scintillation counting with the addition of 3 mL Ready Safe in a Beckman LS Liquid Scintillation Counter, with 40% efficiency.
  • Nonspecific binding of [ 3 H]-SK&F- 107260 was determined in the presence of 2 ⁇ M SK&F- 107260 and was consistently less than 1% of total radioligand input.
  • the IC50 concentration of the antagonist to inhibit 50% binding of [ 3 H]-SK&F- 107260
  • the Kj dissociation constant of the antagonist
  • Kj IC50/O + L/K ⁇ j
  • L and KH were the concentration and the dissociation constant of [ 3 H]-SK&F-107260, respectively.
  • Compounds of the present invention inhibit vitronectin binding to SK&F 107260 in the concentration range of about 2.5 to about 0.001 micomolar.
  • Rat or human aortic smooth muscle cells were used. The cell migration was monitored in a Transwell cell culture chamber by using a polycarbonate membrane with pores of 8 um (Costar). The lower surface of the filter was coated with vitronectin. Cells were suspended in DMEM supplemented with 0.2% bovine serum albumin at a concentration of 2.5 - 5.0 x 10° cells/mL, and were pretreated with test compound at various concentrations for 20 min at 20°C. The solvent alone was used as control. 0.2 mL of the cell suspension was placed in the upper compartment of the chamber. The lower compartment contained 0.6 mL of DMEM supplemented with 0.2% bovine serum albumin.
  • Incubation was carried out at 37°C in an atmosphere of 95% air/5% C0 2 for 24 hr. After incubation, the non-migrated cells on the upper surface of the filter were removed by gentle scraping. The filter was then fixed in methanol and stained with 10% Giemsa stain. Migration was measured either by a) counting the number of cells that had migrated to the lower surface of the filter or by b) extracting the stained cells with 10% acetic acid followed by determining the absorbance at 600 nM.
  • Each experimental group consists of 5-6 adult male Sprague-Dawley rats (250-400g body weight).
  • the rats are thyroparathyroidectomized (by the vendor, Taconic Farms) 7 days prior to use. All rats receive a replacement dose of thyroxine every 3 days.
  • On receipt of the rats circulating ionized calcium levels are measured in whole blood immediately after it has been withdrawn by tail venipuncture into heparinized tubes. Rats are included if the ionized Ca level (measured with a Ciba-Corning model 634 calcium pH analyzer) is ⁇ 1.2 mM/L.
  • Each rat is fitted with an indwelling venous and arterial catheter for the delivery of test material and for blood sampling respectively.
  • each rat is administered either control vehicle or human parathyroid hormone 1-34 peptide (hPTHl-34, dose 1.25 ug/kg/h in saline/0.1% bovine serum albumin, Bachem, Ca) or a mixture of hPTHl-34 and test material, by continuous intravenous infusion via the venous catheter using an external syringe pump.
  • the calcemic response of each rat is measured at two-hourly intervals during the infusion period of 6-8 hours.
  • the medium is aspirated and replaced with murine anti-HLA-DR antibody then diluted 1 :3 in RPMI-1640 medium.
  • the suspension is incubated for 30 mins on ice and mixed frequently.
  • the cells are washed x2 with cold RPMI-1640 followed by centrifugation (1000 rpm, 5 mins at 4°C) and the cells are then transferred to a sterile 15 ml centrifuge tube. The number of mononuclear cells are enumerated in an improved Neubauer counting chamber.
  • Sufficient magnetic beads (5 / mononuclear cell), coated with goat anti-mouse IgG (Dynal, Great Neck, NY) are removed from their stock bottle and placed into 5 ml of fresh medium (this washes away the toxic azide preservative). The medium is removed by immobilizing the beads on a magnet and is replaced with fresh medium.
  • the beads are mixed with the cells and the suspension is incubated for 30 mins on ice. The suspension is mixed frequently. • The bead-coated cells are immobilized on a magnet and the remaining cells
  • Fresh medium is added to the bead-coated cells to dislodge any trapped osteoclasts. This wash process is repeated xlO. The bead-coated cells are discarded.
  • the viable osteoclasts are enumerated in a counting chamber, using fluorescein diacetate to label live cells.
  • a large-bore disposable plastic pasteur pipet is used to add the sample to the chamber.
  • the osteoclasts are pelleted by centrifugation and the density adjusted to the appropriate number in EMEM medium (the number of osteoclasts is variable from tumor to tumor), supplemented with 10% fetal calf serum and 1.7g/liter of sodium bicarbonate.
  • the slices are washed in six changes of warm PBS (10 ml / well in a 6- well plate) and then placed into fresh medium containing the compound treatment or control samples. The samples are incubated at 37°C for 48 hours.
  • TRIP Tartrate resistant acid phosphatase
  • the bone slices containing the attached osteoclasts are washed in phosphate buffered saline and fixed in 2% gluteraldehyde (in 0.2M sodium cacodylate) for 5 mins.
  • the TRAP positive osteoclasts (brick red/ purple precipitate) are enumerated by bright-field microscopy and are then removed from the surface of the dentine by sonication. • Pit volumes are determined using the Nikon/Lasertec ILM21W confocal microscope.
  • the human osteoclasts are enriched and prepared for compound screening as described in the initial 9 steps of Assay 1. For clarity, these steps are repeated hereinbelow.
  • the medium is aspirated and replaced with murine anti-HLA-DR antibody then diluted 1 :3 in RPMI-1640 medium.
  • the suspension is incubated for 30 mins on ice and mixed frequently.
  • the cells are washed x2 with cold RPMI-1640 followed by centrifugation (1000 rpm, 5 mins at 4°C) and the cells are then transferred to a sterile 15 ml centrifuge tube. The number of mononuclear cells are enumerated in an improved Neubauer counting chamber. • .
  • Sufficient magnetic beads (5 / mononuclear cell), coated with goat anti-mouse IgG (Dynal, Great Neck, NY) are removed from their stock bottle and placed into 5 ml of fresh medium (this washes away the toxic azide preservative). The medium is removed by immobilizing the beads on a magnet and is replaced with fresh medium.
  • the beads are mixed with the cells and the suspension is incubated for 30 mins on ice. The suspension is mixed frequently.
  • the bead-coated cells are immobilized on a magnet and the remaining cells (osteoclast-rich fraction) are decanted into a sterile 50 ml centrifuge tube.
  • Fresh medium is added to the bead-coated cells to dislodge any trapped osteoclasts. This wash process is repeated lO. The bead-coated cells are discarded. • The viable osteoclasts are enumerated in a counting chamber, using fluorescein diacetate to label live cells. A large-bore disposable plastic pasteur pipet is used to add the sample to the chamber.
  • the osteoclasts are pelleted by centrifugation and the density adjusted to the appropriate number in EMEM medium (the number of osteoclasts is variable from tumor to tumor), supplemented with 10% fetal calf serum and 1 Jg/liter of sodium bicarbonate.
  • osteoclast preparations are preincubated for 30 minutes at 37°C with test compound (4 doses) or controls.
  • the bone slices are washed in six changes of warm phosphate buffered saline (PBS), to remove non-adherent cells, and are then returned to wells of a 48 well plate containing fresh compound or controls.
  • PBS warm phosphate buffered saline
  • tissue culture plate is then incubated for 48 hours at 37°C.
  • the supernatants from each well are aspirated into individual tubes and are screened in a competitive ELISA that detects the c-telopeptide of type I collagen which is released during the resorption process.
  • This is a commercially available ELISA (Osteometer, Denmark) that contains a rabbit antibody that specifically reacts with an 8- amino acid sequence (Glu-Lys-Ala-His- Asp-Gly-Gly-Arg) that is present in the carboxy-terminal telopeptide of the al-chain of type I collagen.
  • the results are expressed as % inhibition of resorption compared to a vehicle control.
  • the human osteoclasts are enriched and prepared for compound screening as described above in the inital 9 steps of Assay 1. For clarity, these steps are repeated hereinbelow.
  • the cells are washed x2 with cold RPMI- 1640 followed by centrifugation (1000 rpm, 5 mins at 4°C) and the cells are then transferred to a sterile 15 ml centrifuge tube. The number of mononuclear cells are enumerated in an improved Neubauer counting chamber.
  • Sufficient magnetic beads (5 / mononuclear cell), coated with goat anti-mouse IgG (Dynal, Great Neck, NY) are removed from their stock bottle and placed into 5 ml of fresh medium (this washes away the toxic azide preservative). The medium is removed by immobilizing the beads on a magnet and is replaced with fresh medium.
  • the beads are mixed with the cells and the suspension is incubated for 30 mins on ice. The suspension is mixed frequently.
  • the bead-coated cells are immobilized on a magnet and the remaining cells (osteoclast-rich fraction) are decanted into a sterile 50 ml centrifuge tube. • Fresh medium is added to the bead-coated cells to dislodge any trapped osteoclasts.
  • This wash process is repeated xlO.
  • the bead-coated cells are discarded.
  • the viable osteoclasts are enumerated in a counting chamber, using fluorescein diacetate to label live cells. A large-bore disposable plastic pasteur pipet is used to add the sample to the chamber. • The osteoclasts are pelleted by centrifugation and the density adjusted to the appropriate number in EMEM medium (the number of osteoclasts is variable from tumor to tumor), supplemented with 10% fetal calf serum and l Jg/liter of sodium bicarbonate.
  • Osteoclastoma-derived osteoclasts are preincubated with compound (4 doses) or controls at 37°C for 30 minutes.
  • osteopontin-coated slides human or rat osteopontin, 2.5ug/ml
  • Non adherent cells are removed by washing the slides vigorously in phosphate buffered saline and the cells remaining on the slides are fixed in acetone.
  • the osteoclasts are stained for tartrate-resistant acid phosphatase (TRAP), a selective marker for cells of this phenotype (see steps 15 -17), and are enumerated by light microscopy. The results are expressed as % inhibition of adhesion compared to a vehicle control.
  • TRIP tartrate-resistant acid phosphatase
  • HEK293 cells Human embryonic kidney cells (HEK293 cells) were obtained from ATCC (Catalog No. CRL 1573). Cells were grown in Earl's minimal essential medium (EMEM) medium containing Earl's salts, 10% fetal bovine serum, 1 % glutamine and 1% Penicillin- Steptomycin.
  • EMEM Earl's minimal essential medium
  • the growth medium was supplemented with 450 ⁇ g/mL Geneticin (G418 Sulfate, GIBCO-BRL, Bethesda, MD). The cells were maintained in selection medium until the colonies were large enough to be assayed.
  • the cells were immobilized on glass microscope slides by centrifugation, fixed in acetone for 2 min at room temperature and air dried. Specific reactivity with 23C6, a monoclonal antibody specific for the ⁇ v ⁇ complex was demonstrated using a standard indirect immunofluorescence method.
  • Corning 96-well ELISA plates were precoated overnight at 4°C with 0.1 mL of human vitronectin (0.2 ⁇ g/mL in RPMI medium). At the time of the experiment, the plates were washed once with RPMI medium and blocked with 3.5% BSA in RPMI medium for 1 hr at room temperature. Transfected 293 cells were resuspended in RPMI medium, supplemented with 20 mM Hepes, pH 7.4 and 0.1 % BSA at a density of 0.5 x 10 6 cells/mL. 0.1 mL of cell suspension was added to each well and incubated for 1 hr at 37°C, in the presence or absence of various cc v ⁇ 3 antagonists.
  • the vitronectin receptor ⁇ v ⁇ s was purified from human placenta. Receptor preparation was diluted with 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM CaCl 2 , 1 mM MnCl 2 , 1 mM MgCl 2 (buffer A) and was immediately added to 96- well ELISA plates at 0.1 ml per well. 0.1-0.2 ⁇ g of ot v ⁇ 3 was added per well. The plates were incubated overnight at 4°C.
  • the wells were washed once with buffer A and were incubated with 0.1 ml of 3.5% bovine serum albumin in the same buffer for 1 hr at room temperature. Following incubation the wells were aspirated completely and washed twice with 0.2 ml buffer A.
  • the receptors were solubilized with 0.1 ml of 1 % SDS and the bound [ 3 H]-SK&F- 107260 was determined by liquid scintillation counting with the addition of 3 ml Ready Safe in a Beckman LS 6800 Liquid Scintillation Counter, with 40% efficiency.
  • Nonspecific binding of [ 3 H]-SK&F- 107260 was determined in the presence of 2 ⁇ M SK&F- 107260 and was consistently less than 1 % of total radioligand input.
  • the IC50 concentration of the antagonist to inhibit 50% binding of [ 3 H]-SK&F- 107260 was determined by a nonlinear, least squares curve-fitting routine, which was modified from the LUNDON-2 program.
  • Kj dissociation constant of the antagonist
  • the column was washed with 50 mL cold buffer A.
  • the lectin-retained GPIIb-IIIa was eluted with buffer A containing 10% dextrose. All procedures were performed at 4°C.
  • the GPIIb-IIIa obtained was >95% pure as shown by SDS polyacrylamide gel electrophoresis.
  • the GPIIb-IIIa- containing liposomes wee centrifuged at 12,000g for 15 min and resuspended in the dialysis buffer at a final protein concentration of approximately 1 mg/mL. The liposomes were stored at -70C until needed.
  • the binding to the fibrinogen receptor (GPIIb-IIIa) was assayed by an indirect competitive binding method using [ ⁇ HJ-SK&F- 107260 as an RGD-type ligand.
  • the binding assay was performed in a 96-well filtration plate assembly (Millipore Co ⁇ oration, Bedford, MA) using 0.22 um hydrophilic durapore membranes.
  • the wells were precoated with 0.2 mL of 10 ⁇ g/mL polylysine (Sigma Chemical Co., St. Louis, MO.) at room temperature for 1 h to block nonspecific binding.
  • Various concentrations of unlabeled benzazepines were added to the wells in quadruplicate.
  • [ ⁇ Hj-SK&F- 107260 was applied to each well at a final concentration of 4.5 nM, followed by the addition of 1 ⁇ g of the purified platelet GPIIb-IIIa-containing liposomes. The mixtures were incubated for 1 h at room temperature. The GPIIb-IIIa-bound [3H]-SK&F- 107260 was seperated from the unbound by filtration using a Millipore filtration manifold, followed by washing with ice-cold buffer (2 times, each 0.2 mL).
  • IC50 concentration of the antagonist which inhibits specific binding of [ 3 H]-SK&F- 107260 by 50% at equilibrium.
  • Preferred compounds of this invention have an affinity for the vitronectin receptor relative to the fibrinogen receptor of greater than 10: 1. Most preferred compounds have a ratio of activity of greater than 100: 1.
  • CDC1 3 is deuteriochloroform
  • DMSO-d6 is hexadeuteriodimethylsulfoxide
  • CD 3 OD is tetradeuteriomethanol.
  • Infrared (IR) spectra were recorded in transmission mode, and band positions are reported in inverse wavenumbers (cm " I). Mass spectra were obtained using electrospray (ES) or FAB ionization techniques. Elemental analyses were performed either in-house or by Quantitative Technologies Inc., Whitehouse, NJ. Melting points were taken on a Thomas-Hoover melting point apparatus and are uncorrected. All temperatures are reported in degrees Celsius.
  • Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin layer plates were used for thin layer chromatography.
  • ODS refers to an octadecylsilyl derivatized silica gel chromatographic support. 5 ⁇ Apex-ODS indicates an octadecylsilyl derivatized silica gel chromatographic support having a nominal particle size of 5 ⁇ , made by Jones Chromatography, Littleton, Colorado.
  • YMC ODS-AQ® is an ODS chromatographic support and is a registered trademark of YMC Co. Ltd., Kyoto, Japan.
  • PRP-1® is a polymeric (styrene- divinylbenzene) chromatographic support, and is a registered trademark of Hamilton Co., Reno, Nevada.
  • Celite® is a filter aid composed of acid-washed diatomaceous silica, and is a registered trademark of Manville Corp., Denver, Colorado.
  • Ethyl ( ⁇ )-10,l l-dihydro-3-methoxy-5H-dibenzo[a,d]cycloheptene-10-acetate, ethyl ( ⁇ )-10,l l-dihydro-3-hydroxy-5H-dibenzo[a,d]cycloheptene-10-acetate, and ethyl (+)- 10,l l-dihydro-3-(trifluoromethanesulfonyloxy)-5H-dibenzota,d]cycloheptene-10-acetate were prepared according to WO 9701540-A1.
  • 6-picoline (10.31 g, 46.38 mmole) in dry THF (46 mL) was added dropwise over 10 min.
  • Methanesulfonyl chloride (0.17 mL, 2.20 mmole) was added dropwise to a solution of 2-[N-(3-hydroxy-l-propyl)-N-(r -butoxycarbonyl)amino]pyridine-N-oxide (0.50 g, 1.86 mmole) and pyridine (0.23 mL, 2.84 mmole) in CHC1 3 (5 mL, dried over K 2 C0 3 ) at 0°C. When complete by TLC, the reaction was diluted with CHC1 3 , washed with ice water, dried (Na 2 S0 4 ), and concentrated.
  • Acetone (4.2 L) was chilled to 10°C, and a solution of 6-methoxy-l-phenylindene (271 g, 1.22 mole) in acetone (1.8 L) was added over 1.5 hr concurrently with Jones reagent (1.8 L, prepared from Cr0 3 (470 g, 4.70 mole), H 2 0 (1 L), and cone H 2 S0 4 (405 mL)).
  • Jones reagent (1.8 L, prepared from Cr0 3 (470 g, 4.70 mole), H 2 0 (1 L), and cone H 2 S0 4 (405 mL)).
  • 4 % Aqueous Os0 4 (153 mL) was added to the resulting mixture in two portions, one at the onset of addition and the second at the mid-point of the addition, maintaining the temperature of the reaction mixture below 15°C.
  • reaction mixture was warmed to 22°C and stirred for 1.5 h, during which time a mild exotherm increased the temperature to 28°C.
  • the reaction mixture was then cooled to below 20°C and isopropanol (1 L) was added, dropwise initially and rapidly after the initial exotherm diminished. Stirring became difficult during this phase.
  • the temperature reached 32°C during the isopropanol addition.
  • H 2 0 (2 L) was added and the mixture was transferred to a separatory funnel. Additional H 2 0 was added to dissolve the precipitated chromous acid, and the mixture was extracted with CH 2 C1 2 (2 L). The organic (upper) layer was separated and the aqueous phase was extracted with CH 2 C1 2 (2 x 1 L).
  • reaction mixture was stirred for 10 min, then a solution of 10,1 l-dihydro-3-methoxy-5H- dibenzo[a,d]cyclohepten-10-one (119.2 g, 0.50 mol) in anhydrous THF (1.26 L) was added dropwise over 40 min. The temperature was maintained below -65°C during all of these additions.
  • the reaction mixture was stirred for 20 min at -65 to -70°C and then was poured into saturated aqueous NH C1 (6.2 L) with vigorous stirring. The organic layer was separated and the aqueous phase was extracted with EtOAc (2 x 1 L).
  • the mixture was placed in a 2.5 L pressure bottle containing 5% Pd/C (20 g, 0.0094 mole), and the resulting mixture was shaken at 35°C under hydrogen on a Parr hydrogenation apparatus equipped with a jacket heater. After 18 hr, the reaction was cooled to ambient temperature, and the catalyst was removed by filtration. The filtrate was concentrated to give a light yellow oil (85.1 g).
  • the pH was adjusted to 7 with 1.0 N HCl, and the mixture was stirred briskly to convert the initially-formed gummy precipitate into a solid. Trituration with a glass rod and a spatula aided in this transformation. The pH of the resulting mixture was readjusted to 7, and the solid was collected and washed with plenty of H 2 0. The filtrate was concentrated and the residue was dissolved in H 2 0 with the aid of a little 1.0 N NaOH. The pH was adjusted to 7 to afford a small second crop.
  • the solution was concentrated to near dryness by rotary evaporation to precipitate out the product.
  • the supernatant was decanted off and the remaining gummy solid was dried under vacuum and redissolved in 1 : 1 methanol/CHCl .
  • the clear solution was then reconcentrated by rotary evaporation and thoroughly dried under vacuum.
  • Example 6 According to the procedure of Example 6 (a), except substituting ⁇ -(methylamino)- 2-pyridylethanol for the 2-[(3-hydroxy-l-propyl)amino]pyridine-N-oxide, and ethyl (S)- 10,11 -dihydro-3-hydroxy-5H-dibenzo[a,d]cycloheptene- 10-acetate for ethyl (R)- 10, 11- dihydro-3-hydroxy-5H-dibenzo[a,d]cycloheptene-l 0-acetate, the title compound was obtained as colorless oil following silica gel chromatography (0.2 - 2% MeOH/CH 2 Cl 2 ): MS (ES) 431.2 (M + H)+.
  • Example 6 (a) According to the procedure of Example 6 (a), except substituting l-[(3-hydroxy-l- propyl)amino]-isoquinoline N-oxide for the 2-[(3-hydroxy- 1 -propyl)amino]pyridine-N- oxide, and substituting ethyl ( ⁇ )-10,l l-dihydro-3-hydroxy-5H-dibenzo[a,d]cycloheptene- 10-acetate for the ethyl (R)-10,l l-dihydro-3-hydroxy-5H-dibenzo[a,d]cycloheptene- 10- acetate, the title compound was prepared as a pale yellow oil: MS (ES) m/e 497.2 (M + H)+.
  • Example 6 According to the procedure of Example 6 (b), except substituting ethyl ( ⁇ )-10,l 1- dihydro-3-[3-(l-oxoisoquinoline-l-ylamino)-l-propyloxy]-5H-dibenzo[a,d]cycloheptene- 10-acetate for the ethyl (R)-10,l l-dihydro-3-[3-(l-oxopyridin-2-ylamino)-l-propyloxy]- 5H-dibenzo[a,d]cycloheptene- 10-acetate, the title compound was prepared as a clear oil: MS (ES) m/e 481.3(M + H)+.
  • Example 6 (c) According to the procedure of Example 6 (c), except substituting ethyl ( ⁇ )-10, 11- dihydro-3-[3-(isoquinoline-l -ylamino)- l-propyloxy]-5H-dibenzo[a,d]cycloheptene- 10- acetate for the ethyl (R)-10,l l-dihydro-3-[3-(pyridin-2-ylamino)-l-propyloxy]-5H- dibenzo[a,d]cycloheptene- 10-acetate, the title compound was prepared as an amber solid: MS (ES) m e 453.2(M + H)+. Anal.
  • Example 6 (c) According to the procedure of Example 6 (c), except substituting ethyl ( ⁇ )-10, 11- dihydro-3-[3-[4-(ethylthio)pyridin-2-ylamino]-l-propyloxy]-5H-dibenzo[a,d]cycloheptene- 10-acetate for the ethyl (R)- 10,11 -dihydro-3-[3-(pyridin-2-ylamino)-l -propyloxy ]-5H- dibenzo[a,d]cycloheptene- 10-acetate, the title compound was prepared as a yellow: 1H NMR (400 MHz, DMSO-d 6 ) ⁇ 7.77 - 7.76 (d, 1 H), 7.17 - 7.15 (d, 1 H), 7.13 - 7.12 (d, 2 H), 7.08 - 7.07 (m, 1 H), 6.96 - 6.94(d, 1 H), 6.81 - 6.80 (s,
  • Example 6 According to the procedure of Example 6 (b), except substituting ethyl ( ⁇ )-10,l 1- dihydro-2-methyl-3-[3-(l-oxopyridin-2-ylamino)-l-propyloxy]-5H- dibenzo[a,d]cycloheptene- 10-acetate for the ethyl (R)-10,l l-dihydro-3-[3-(l-oxopyridin-2- ylamino)-l-propyloxy]-5H-dibenzo[a,d]cycloheptene- 10-acetate, the title compound was prepared as an off-white solid: MS (ES) m e 417.3 (M + H)+.
  • Example 6 According to the procedure of Example 6 (a), except substituting ethyl ( ⁇ )-10,l 1- dihydro-2-(dimethylamino)methyl-7-fluoro-3-hydroxy-5H-dibenzo[a,d]cycloheptene- 10- acetate for the ethyl (R)-10,l l-dihydro-3-hydroxy-5H-dibenzo[a,d]cycloheptene- 10-acetate ethyl, the title compound was obtained following silica gel chromatography (gradient: 1 : 1 EtOAc hexanes, then EtOAc, then 20% MeOH/CH 2 Cl 2 , then 30% MeOH/CH 2 Cl 2 ): MS (ES) m/e 522.3 (M + H)+.
  • Example 13 (b) According to the procedure of Example 13 (b), except substituting isopropyl (S)- 10,1 1 -dihydro-3-[3-[4-(2-propyloxy)- 1 -oxopyridin-2-ylamino]- 1 -propyloxy ]-5H- dibenzo[a,d]cycloheptene- 10-acetate for the ethyl (S)-10,l l-dihydro-3-[3-(4-methyl-l- oxopyridin-2-ylamino)- 1 -propyloxy]-5H-dibenzo[a,d]cycloheptene- 10-acetate, the title compound was obtained as slightly yellow oil following silica gel chromatography (5% MeOH/CH 2 Cl 2 ): MS (ES) 503.4 (M + H)+.
  • Example 15 According to the procedure of Example 13 (c), except substituting isopropyl (S)- 10,l l-dihydro-3-[3-[4-(2-propyloxy)pyridin-2-ylamino]-l-propyloxy]-5H- dibenzo[a,d]cycloheptene-10-acetate for the ethyl (S)-10,l l-dihydro-3-[3-(4- mefhylpyridin-2-ylamino)- 1 -propyloxy]-5H-dibenzo[a,d]cycloheptene- 10-acetate, the title compound was obtained as white powder: MS (ES) 461.3 (M + H) + . Anal. Calcd for C 8 H 32 N 2 0 • 0.96 HCl: C, 67.86; H, 6.70; N, 5.65. Found: C, 68.26; H, 6.86; N, 5.25.
  • Example 15 Anal. Calcd for
  • Example 16 According to the procedure of Example 13 (c), except substituting ethyl (S)-10,l 1- dihydro-3-[3-(4-chloropyridin-2-ylamino)-l-propyloxy]-5H-dibenzo[a,d]cycloheptene- 10- acetate for the ethyl (S)-10,l l-dihydro-3-[3-(4-methylpyridin-2-ylamino)-l-propyloxy]- 5H-dibenzo[a,d]cycloheptene- 10-acetate, the title compound was obtained as off-white powder: MS (ES) 437.2 (M + H)+. Anal. Calcd for C 25 H 25 N 2 0 3 • 1.0 HCl: C, 63.43; H, 5.54; N, 5.92. Found: C, 63.11; H, 5.82; N, 5.62.
  • Example 16 Anal. Calcd for C 25 H 25 N 2
  • Example 13 (b) According to the procedure of Example 13 (b), except substituting ethyl (S)-10,l 1- dihydro-3-[3-[4-(dimethylamino)-l-oxopyridin-2-ylamino]-l-propyloxy]-5H- dibenzo[a,d]cycloheptene- 10-acetate for the ethyl (S)-10,l l-dihydro-3-[3-(4-methyl-l- oxopyridin-2-ylamino)- 1 -propyloxy ]-5H-dibenzo[a,d]cycloheptene- 10-acetate, the title compound was obtained as white powder following silica gel chromatography (8% MeOH/CH 2 Cl 2 ): MS (ES) 474.3 (M + H)+.
  • Example 13 (c) According to the procedure of Example 13 (c), except substituting ethyl (S)-10, 1 1- dihydro-3-[3-[4-(dimethylamino)pyridin-2-ylamino]-l-propyloxy]-5H- dibenzo[a,d]cycloheptene- 10-acetate for the ethyl (S)-10,l l-dihydro-3-[3-(4- methylpyridin-2-ylamino)- 1 -propyloxy ]-5H-dibenzo[a,d]cycloheptene- 10-acetate, the title compound was obtained as white powder: MS (ES) 446.2 (M + H) + . Anal. Calcd for C 27 H 31 N 3 0 3 • 0.5 H 2 0 • 1.0 HCl: C, 66.04; H, 6.77; N, 8.56. Found: C, 65.96; H, 6.60; N, 8.26.
  • Example 2 (a) According to the procedure of Example 2 (a), except substituting ethyl (S)-10, 1 1- dihydro-3-[3-(4-nitro-l-oxopyridin-2-ylamino)-l-propyloxy]-5H- dibenzo[a,d]cycloheptene- 10-acetate (496.9 mg, 1.01 mmol) for the ethyl ( ⁇ )-10, 11- dihydro-3-[3-(4-nitro- 1 -oxopyridin-2-ylamino)- 1 -propyloxy]-5H- dibenzo[a,d]cycloheptene- 10-acetate, and using 0.53 M NaOEt (4.0 mL, 2.12 mmol) and absolute ethanol (10 mL) in the displacement reaction, the title compound (456.2 mg, 92%) was prepared: MS (ES) m/e 491 (M + H)+.
  • Example 2 (b) According to the procedure of Example 2 (b), except substituting ethyl (S)-10,l 1- dihydro-3-[3-(4-ethoxy-l-oxopyridin-2-ylamino)-l-propyloxy]-5H- dibenzo[a,d]cycloheptene- 10-acetate (456.2 mg, 0.93 mmole) for the ethyl ( ⁇ )-10,l 1- dihydro-3-[3-(4-ethoxy-l-oxopyridin-2-ylamino)-l-propyloxy]-5H- dibenzo[a,d]cycloheptene-10-acetate, the title compound (475.2 mg, quantitative) was prepared: MS (ES) m/e 475 (M + H)+.
  • Example 6 According to the procedure of Example 6 (b), except substituting ethyl ( ⁇ )- 10,11- dihydro-7-fluoro-3-[3-( 1 -oxopyridin-2-ylamino)- 1 -propyloxy]-5H- dibenzo[a,d]cycloheptene- 10-acetate for the ethyl (R)-10,l l-dihydro-3-[3-(l-oxopyridin-2- ylamino)-l-propyloxy]-5H-dibenzo[a,d]cycloheptene- 10-acetate, the title compound was obtained: MS (ES) m e 449.2 (M + H) + .
  • Example 6 According to the procedure of Example 6 (a), except substituting ethyl ( ⁇ )-10,l 1- dihydro-3-hydroxy-6-methyl-5H-dibenzo[a,d]cycloheptene- 10-acetate for the ethyl (R)- 10,1 l-dihydro-3-hydroxy-5H-dibenzo[a,d]cycloheptene-10-acetate, the title compound was obtained as a colorless oil following silica gel chromatography (gradient: 1 : 1 EtOAc/hexanes, then EtOAc, then 4% MeOH/CH 2 Cl 2 ): MS (ES) m e 461.3 (M + H)+.
  • Example 6 According to the procedure of Example 6 (b), except substituting ethyl ( ⁇ )-10, 11- dihydro-6-methyl-3-[3-( 1 -oxopyridin-2-ylamino)- l-propyloxy]-5H- dibenzo[a,d]cycloheptene- 10-acetate for the ethyl (R)-10,l l-dihydro-3-[3-(l-oxopyridin-2- ylamino)-l-propyloxy]-5H-dibenzo[a,d]cycloheptene- 10-acetate, the title compound was obtained following silica gel chromatography (1 % MeOH/CH 2 Cl 2 ): MS (ES) m/e 445.3 (M + H)+.
  • Example 1(a) (0.23 g, 1.51 mmol) and di-isopropylazadicarboxylate (0.29 mL, 1.50 mmol) in CH 2 C1 2 (7.5 mL) was added dropwise to a solution of triphenylphosphine (0.39 g, 1.50 mmol) and ethyl 2-[(105)-3-hydroxy-10,l l-dihydro-5//- dibenzo[ ⁇ ,Jlcyclohepten-10-yl]acetate (0.30 g, 1.00 mmol) in CH 2 C1 2 (5 mL) at 0 °C. The ice bath was removed and the reaction was allowed to warm to RT.
  • a preparation which contains 20 mg of the compound of Example 1 as a sterile dry powder is prepared as follows: 20 mg of the compound is dissolved in 15 mL of distilled water. The solution is filtered under sterile conditions into a 25 mL multi-dose ampoule and lyophilized. The powder is reconstituted by addition of 20 mL of 5% dextrose in water (D5W) for intravenous or intramuscular injection. The dosage is thereby determined by the injection volume. Subsequent dilution may be made by addition of a metered volume of this dosage unit to another volume of D5W for injection, or a metered dose may be added to another mechanism for dispensing the drug, as in a bottle or bag for IV drip infusion or other injection-infusion system.
  • D5W dextrose in water
  • a capsule for oral administration is prepared by mixing and milling 50 mg of the compound of Example 1 with 75 mg of lactose and 5 mg of magnesium stearate. The resulting powder is screened and filled into a hard gelatin capsule.
  • a tablet for oral administration is prepared by mixing and granulating 20 mg of sucrose, 150 mg of calcium sulfate dihydrate and 50 mg of the compound of Example 1 with a 10% gelatin solution.
  • the wet granules are screened, dried, mixed with 10 mg starch, 5 mg talc and 3 mg stearic acid; and compressed into a tablet.

Abstract

L'invention a trait à des composés représentés par la formule (I) qui constituent des antagonistes du récepteur de la vitronectine et sont utiles dans le traitement de l'ostéoporose, ou à un sel pharmaceutiquement acceptable de ces composés. Dans la formule, A est CH2 ou O; R1 est H, halo ou alkyle en C¿1-6; R?2 est H, alkyle en C¿1-6? ou CH2NR'R'; X est O ou CH2; Y est (a), (b), (c), (d), (e), (f) ou (g); G est NR', S ou O; R' est H, alkyle en C1-6, OC1-6alkyle, SC1-6alkyle, NR'R' ou halo; chaque R' est indépendamment H ou alkyle en C1-6, et s est 0, 1 ou 2.
PCT/US1998/019466 1997-09-19 1998-09-18 Antagonistes du recepteur de la vitronectine WO1999015508A1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CA002303487A CA2303487A1 (fr) 1997-09-19 1998-09-18 Antagonistes du recepteur de la vitronectine
EA200000336A EA200000336A1 (ru) 1997-09-19 1998-09-18 Антагонисты рецептора витронектина
NZ503389A NZ503389A (en) 1997-09-19 1998-09-18 Vitronectin receptor antagonists comprising substituted dibenzo[a,d]cycloheptene or dibenzo[b,f]oxepine and their use as antagonists of alpha-v-beta-3 receptors or alpha-v-beta-5 receptors
EP98947116A EP1025090A4 (fr) 1997-09-19 1998-09-18 Antagonistes du recepteur de la vitronectine
APAP/P/2000/001766A AP2000001766A0 (en) 1997-09-19 1998-09-18 Vitronectin receptor anatagonists.
BR9812340-8A BR9812340A (pt) 1997-09-19 1998-09-18 Antagonistas de receptor de vitronectina
SK408-2000A SK4082000A3 (en) 1997-09-19 1998-09-18 COMPOUND CONTAINING DIBENZOCYCLOHEPTENE NUCLEUS, PROCESS FOR THEì (54) PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITION CONTA
KR1020007002901A KR20010024141A (ko) 1997-09-19 1998-09-18 비트로넥틴 수용체 길항 물질
AU93972/98A AU738433B2 (en) 1997-09-19 1998-09-18 Vitronectin receptor antagonists
IL13502898A IL135028A0 (en) 1997-09-19 1998-09-18 Vitronectin receptor antagonists
JP2000512816A JP2001517658A (ja) 1997-09-19 1998-09-18 ビトロネクチン受容体アンタゴニスト
HU0003641A HUP0003641A3 (en) 1997-09-19 1998-09-18 Dibenzocycloheptene derivatives as vitronectin receptor antagonists, process for producing them and pharmaceutical compositions containing them
NO20001407A NO20001407D0 (no) 1997-09-19 2000-03-17 Vitronectin-reseptor-antagonister
BG104314A BG104314A (en) 1997-09-19 2000-04-07 Vitronectin receptor antagonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5934297P 1997-09-19 1997-09-19
US60/059,342 1997-09-19
US6343897P 1997-10-29 1997-10-29
US60/063,438 1997-10-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09508574 A-371-Of-International 2000-03-13
US10/022,987 Continuation US6576643B2 (en) 1997-09-19 2001-12-17 Vitronectin receptor antagonists

Publications (1)

Publication Number Publication Date
WO1999015508A1 true WO1999015508A1 (fr) 1999-04-01

Family

ID=26738652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/019466 WO1999015508A1 (fr) 1997-09-19 1998-09-18 Antagonistes du recepteur de la vitronectine

Country Status (26)

Country Link
EP (1) EP1025090A4 (fr)
JP (1) JP2001517658A (fr)
KR (1) KR20010024141A (fr)
CN (1) CN1278250A (fr)
AP (1) AP2000001766A0 (fr)
AR (1) AR015446A1 (fr)
AU (1) AU738433B2 (fr)
BG (1) BG104314A (fr)
BR (1) BR9812340A (fr)
CA (1) CA2303487A1 (fr)
CO (1) CO5011087A1 (fr)
DZ (1) DZ2609A1 (fr)
EA (1) EA200000336A1 (fr)
HU (1) HUP0003641A3 (fr)
ID (1) ID24162A (fr)
IL (1) IL135028A0 (fr)
MA (1) MA26547A1 (fr)
NO (1) NO20001407D0 (fr)
NZ (1) NZ503389A (fr)
OA (1) OA11341A (fr)
PE (1) PE122699A1 (fr)
PL (1) PL339381A1 (fr)
SK (1) SK4082000A3 (fr)
TR (1) TR200000721T2 (fr)
TW (1) TW513303B (fr)
WO (1) WO1999015508A1 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977735A1 (fr) * 1997-01-08 2000-02-09 Smithkline Beecham Corporation Antagonistes du recepteur de vitronectine
WO2001010847A2 (fr) * 1999-08-09 2001-02-15 Basf Aktiengesellschaft Nouveaux antagonistes des recepteurs integrines
US6232308B1 (en) 1999-02-03 2001-05-15 Merck & Co., Inc. Bezazepine derivatives as αv integrin receptor antagonists
FR2806082A1 (fr) * 2000-03-07 2001-09-14 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2001096310A1 (fr) * 2000-06-15 2001-12-20 Pharmacia Corporation Derives d'acide alkanoique dihydrostilbene utilises comme antagonistes de la vitronectine
EP1218005A2 (fr) * 1999-09-07 2002-07-03 SmithKline Beecham Corporation Antagonistes du recepteur de la vitronectine
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
EP1331937A2 (fr) * 2000-10-24 2003-08-06 Merck & Co., Inc. Antagoniste du recepteur de l'integrine de la dibenzoxazepine alpha v
WO2004004715A2 (fr) * 2002-07-09 2004-01-15 Glaxosmithkline Spa Nouveau procede et composes associes
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO2005120477A2 (fr) 2004-06-07 2005-12-22 Merck & Co., Inc. N- (2-benzyl) -2-phenylbutanamides modulant le recepteur d'androgene
WO2007084670A2 (fr) 2006-01-18 2007-07-26 Merck Patent Gmbh Traitement specifique utilisant des ligands de l’integrine destine a traiter un cancer
WO2008087025A2 (fr) 2007-01-18 2008-07-24 Merck Patent Gmbh Thérapie spécifique et médicament utilisant des ligands d'intégrine ou traitant le cancer
WO2010136168A2 (fr) 2009-05-25 2010-12-02 Merck Patent Gmbh Administration continue de ligands d'intégrines pour le traitement du cancer
EP2292251A1 (fr) 2001-04-24 2011-03-09 Merck Patent GmbH Polythérapie à base d'agents antiangiogéniques et de facteur de nécrose tumorale TNF-alpha
US8110683B2 (en) 2002-08-16 2012-02-07 Janssen Pharmaceutica N.V. Piperidinyl compounds that selectively bind integrins
WO2015181676A1 (fr) 2014-05-30 2015-12-03 Pfizer Inc. Dérivés carbonitriles en tant que modulateurs sélectifs du récepteur des androgènes
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3335148A (en) * 1966-02-17 1967-08-08 Lilly Co Eli 9(3-pyridyl)derivative of fluorene, 9-fluorenol, xanthene, 9-xanthenol and the corresponding nonphytotoxic acid addition salts thereof
US3726870A (en) * 1964-02-18 1973-04-10 Hoffmann La Roche 10-carbamoyl-dibenzo(a,d)cyclohepta(1,4,6)trien-5-ones
US5659033A (en) * 1995-09-13 1997-08-19 Neurogen Corporation N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands
US5780486A (en) * 1995-04-07 1998-07-14 Novo Nordisk A/S Heterocyclic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE238996T1 (de) * 1995-06-29 2003-05-15 Smithkline Beecham Corp Integrin-rezeptor-antagonisten
JP2001501951A (ja) * 1996-10-07 2001-02-13 スミスクライン・ビーチャム・コーポレイション 骨形成刺激方法
CO4920232A1 (es) * 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3726870A (en) * 1964-02-18 1973-04-10 Hoffmann La Roche 10-carbamoyl-dibenzo(a,d)cyclohepta(1,4,6)trien-5-ones
US3335148A (en) * 1966-02-17 1967-08-08 Lilly Co Eli 9(3-pyridyl)derivative of fluorene, 9-fluorenol, xanthene, 9-xanthenol and the corresponding nonphytotoxic acid addition salts thereof
US5780486A (en) * 1995-04-07 1998-07-14 Novo Nordisk A/S Heterocyclic compounds
US5659033A (en) * 1995-09-13 1997-08-19 Neurogen Corporation N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1025090A4 *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977735A4 (fr) * 1997-01-08 2000-04-05 Smithkline Beecham Corp Antagonistes du recepteur de vitronectine
EP0977735A1 (fr) * 1997-01-08 2000-02-09 Smithkline Beecham Corporation Antagonistes du recepteur de vitronectine
US6232308B1 (en) 1999-02-03 2001-05-15 Merck & Co., Inc. Bezazepine derivatives as αv integrin receptor antagonists
WO2001010847A3 (fr) * 1999-08-09 2001-11-01 Basf Ag Nouveaux antagonistes des recepteurs integrines
WO2001010847A2 (fr) * 1999-08-09 2001-02-15 Basf Aktiengesellschaft Nouveaux antagonistes des recepteurs integrines
US7105508B1 (en) 1999-08-09 2006-09-12 Abbott Gmbh & Co. Kg Integrin receptors antagonists
JP4685307B2 (ja) * 1999-09-07 2011-05-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー ビトロネクチン受容体アンタゴニスト
EP1218005A2 (fr) * 1999-09-07 2002-07-03 SmithKline Beecham Corporation Antagonistes du recepteur de la vitronectine
EP1218005A4 (fr) * 1999-09-07 2002-10-09 Smithkline Beecham Corp Antagonistes du recepteur de la vitronectine
JP2003508516A (ja) * 1999-09-07 2003-03-04 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US6846833B2 (en) * 2000-03-07 2005-01-25 Les Laboratories Servier Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same
FR2806082A1 (fr) * 2000-03-07 2001-09-14 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CZ301808B6 (cs) * 2000-03-07 2010-06-30 Les Laboratoires Servier Bicyklické slouceniny, antagonistické receptoru vitronektinu, zpusob jejich prípravy a farmaceutické prostredky, které je obsahují
WO2001079172A1 (fr) * 2000-03-07 2001-10-25 LES LABORATOIRES SERVIER Departament Brevets/Fontanes Composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions qui les contiennent
US6720315B2 (en) 2000-06-15 2004-04-13 Pharmacia Corporation Dihydrostilbene alkanoic acid derivatives
WO2001096310A1 (fr) * 2000-06-15 2001-12-20 Pharmacia Corporation Derives d'acide alkanoique dihydrostilbene utilises comme antagonistes de la vitronectine
US6833366B1 (en) 2000-06-15 2004-12-21 Pharmacia Corporation Dihydrostilbene alkanoic acid derivatives
EP1331937A4 (fr) * 2000-10-24 2004-07-21 Merck & Co Inc Antagoniste du recepteur de l'integrine de la dibenzoxazepine alpha v
EP1331937A2 (fr) * 2000-10-24 2003-08-06 Merck & Co., Inc. Antagoniste du recepteur de l'integrine de la dibenzoxazepine alpha v
EP2292251A1 (fr) 2001-04-24 2011-03-09 Merck Patent GmbH Polythérapie à base d'agents antiangiogéniques et de facteur de nécrose tumorale TNF-alpha
WO2004004715A3 (fr) * 2002-07-09 2004-05-06 Glaxosmithkline Spa Nouveau procede et composes associes
WO2004004715A2 (fr) * 2002-07-09 2004-01-15 Glaxosmithkline Spa Nouveau procede et composes associes
US8110683B2 (en) 2002-08-16 2012-02-07 Janssen Pharmaceutica N.V. Piperidinyl compounds that selectively bind integrins
WO2005120477A2 (fr) 2004-06-07 2005-12-22 Merck & Co., Inc. N- (2-benzyl) -2-phenylbutanamides modulant le recepteur d'androgene
EP2338518A1 (fr) 2006-01-18 2011-06-29 Merck Patent GmbH Thérapie spécifique utilisant des ligands d'intégrine pour traiter le cancer
EP2335733A1 (fr) 2006-01-18 2011-06-22 Merck Patent GmbH Thérapie spécifique utilisant des ligands d'intégrine pour traiter le cancer
WO2007084670A2 (fr) 2006-01-18 2007-07-26 Merck Patent Gmbh Traitement specifique utilisant des ligands de l’integrine destine a traiter un cancer
WO2008087025A2 (fr) 2007-01-18 2008-07-24 Merck Patent Gmbh Thérapie spécifique et médicament utilisant des ligands d'intégrine ou traitant le cancer
EP2441464A1 (fr) 2007-01-18 2012-04-18 Merck Patent GmbH Thérapie spécifique et médicament utilisant des ligands d'intégrine pour traiter le cancer
EP2578225A1 (fr) 2007-07-18 2013-04-10 Merck Patent GmbH Thérapie spécifique et médicament utilisant des ligands dýintégrine pour traiter le cancer
WO2010136168A2 (fr) 2009-05-25 2010-12-02 Merck Patent Gmbh Administration continue de ligands d'intégrines pour le traitement du cancer
WO2015181676A1 (fr) 2014-05-30 2015-12-03 Pfizer Inc. Dérivés carbonitriles en tant que modulateurs sélectifs du récepteur des androgènes
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Also Published As

Publication number Publication date
DZ2609A1 (fr) 2003-03-01
AU738433B2 (en) 2001-09-20
CN1278250A (zh) 2000-12-27
ID24162A (id) 2000-07-13
TW513303B (en) 2002-12-11
TR200000721T2 (tr) 2000-11-21
OA11341A (en) 2003-12-10
PL339381A1 (en) 2000-12-18
AU9397298A (en) 1999-04-12
AR015446A1 (es) 2001-05-02
MA26547A1 (fr) 2004-12-20
NZ503389A (en) 2002-03-28
NO20001407L (no) 2000-03-17
BG104314A (en) 2001-01-31
EP1025090A4 (fr) 2000-11-08
SK4082000A3 (en) 2000-09-12
NO20001407D0 (no) 2000-03-17
JP2001517658A (ja) 2001-10-09
KR20010024141A (ko) 2001-03-26
AP2000001766A0 (en) 1998-09-18
BR9812340A (pt) 2001-12-18
CO5011087A1 (es) 2001-02-28
EA200000336A1 (ru) 2000-10-30
CA2303487A1 (fr) 1999-04-01
PE122699A1 (es) 2000-02-12
EP1025090A1 (fr) 2000-08-09
IL135028A0 (en) 2001-05-20
HUP0003641A3 (en) 2002-10-28
HUP0003641A2 (en) 2001-03-28

Similar Documents

Publication Publication Date Title
AU733417B2 (en) Vitronectin receptor antagonists
US6191304B1 (en) Vitronectin receptor antagonists
AU738433B2 (en) Vitronectin receptor antagonists
AU9577498A (en) Vitronectin receptor antagonist
CA2304000A1 (fr) Antagoniste du recepteur de la vitronectine
EP1146874B1 (fr) Antagoniste du recepteur vitronectine
US6576643B2 (en) Vitronectin receptor antagonists
NZ517296A (en) Vitronectin receptor antagonists
US20020019387A1 (en) Vitronectin receptor antagonist
US6881736B1 (en) Vitronectin receptor antagonists
MXPA00002700A (en) Vitronectin receptor antagonists
US20030087894A1 (en) Vitronectin receptor antagonist
CZ2000979A3 (cs) Antagonista vitronektinového receptoru

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 135028

Country of ref document: IL

Ref document number: 98810811.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CZ EE GE HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000/00721

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 09508574

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2303487

Country of ref document: CA

Ref document number: 2303487

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 503389

Country of ref document: NZ

Ref document number: 93972/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/002700

Country of ref document: MX

Ref document number: 1200000225

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2000 512816

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 4082000

Country of ref document: SK

Ref document number: PV2000-979

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020007002901

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1998947116

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200000336

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1998947116

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2000-979

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007002901

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 93972/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998947116

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020007002901

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2000-979

Country of ref document: CZ